A historic shift in federal drug policy is underway. Following an executive order signed on December 18, 2025, the Trump administration has directed an expedited move to reclassify cannabis from Schedule I to Schedule III. This monumental decision is set to reshape the industry by dismantling long-standing financial barriers and introducing first-of-its-kind federal healthcare support for cannabinoid therapies.